IL-27 Counteracts Neuropathic Pain Development Through Induction of IL-10

Neuroimmune-glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain proce...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 3059
Main Authors Fonseca, Miriam M, Davoli-Ferreira, Marcela, Santa-Cecília, Flávia, Guimarães, Rafaela M, Oliveira, Francisco F B, Kusuda, Ricardo, Ferreira, David W, Alves-Filho, José C, Cunha, Fernando Q, Cunha, Thiago M
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.01.2020
Subjects
cytokines
glial cells
IL-10
IL-27
Immunology
macrophages
neuropathic pain
IL-27
glial cells
macrophages
neuropathic pain
cytokines
IL-10
Online AccessGet full text

Cover

More Information
Summary:Neuroimmune-glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain process. Here, we found that neuropathic pain caused by peripheral nerve injury (spared nerve injury model; SNI), was enhanced in IL-27-deficient mice, whereas nociceptive pain is similar to that of wild-type mice. SNI induced an increase in the expression of IL-27 and its receptor subunit ( ) in the sensory ganglia and spinal cord. IL-27 receptor was expressed mainly in resident macrophage, microglia, and astrocytes of the sensory ganglia and spinal cord, respectively. Finally, we identify that the antinociceptive effect of IL-27 was not observed in IL-10 mice. These results provided evidence that IL-27 is a cytokine produced after peripheral nerve injury that counteracts neuropathic pain development through induction of the antinociceptive cytokine IL-10. In summary, our study unraveled the role of IL-27 as a regulatory cytokine that counteracts the development of neuropathic pain after peripheral nerve damage. In conclusion, they indicate that immunotherapies based on IL-27 could emerge as possible therapeutic approaches for the prevention of neuropathic pain development after peripheral nerve injury.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology
Edited by: Felipe Almeida Pinho Ribeiro, Harvard Medical School, United States
Present address: Miriam M. Fonseca, Pain Mechanisms Laboratory, Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, United States
Reviewed by: Felipe J. Nobre Lelis, Brigham and Women's Hospital and Harvard Medical School, United States; Rafael Gonzalez-Cano, Boston Children's Hospital and Harvard Medical School, United States; Larissa Staurengo-Ferrari, University of California, San Francisco, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.03059